Description: Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Home Page: www.plustherapeutics.com
PSTV Technical Analysis
4200 Marathon Boulevard
Austin,
TX
78756
United States
Phone:
737 255 7194
Officers
| Name | Title |
|---|---|
| Dr. Marc H. Hedrick M.D. | Pres, CEO & Director |
| Mr. Andrew J. Sims | VP & CFO |
| Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Medical Officer & Sr. VP |
| Ms. Desiree Smith | Corp. Controller, Principal Financial & Accounting Officer |
| Dr. John K. Fraser | Chief Scientist |
| Mr. Russ Havranek M.B.A., M.S. | VP of Corp. Strategy, New Product Planning & Investor Relations |
| Mr. Gary S. Titus CPA | Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0313 |
| Price-to-Sales TTM: | 143.6115 |
| IPO Date: | 2000-11-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 14 |